Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Rhea-AI Summary

Enliven Therapeutics (Nasdaq: ELVN) has announced it will present five posters at the 2025 AACR Annual Meeting in Chicago from April 25-30, 2025. The presentations will showcase their pipeline of small molecule therapeutics, including:

- ELVN-002: A selective HER2 inhibitor with potential enhanced efficacy in combination with antibody-drug conjugates
- ELVN-001: A selective ABL1 tyrosine kinase inhibitor for chronic myeloid leukemia treatment
- ELV-3111: A type 1 pan-RAF inhibitor for NRAS and BRAF mutant cancers

The presentations will cover pharmacokinetics, drug resistance mechanisms, and combination therapy approaches. All posters will be presented on April 29, 2025, across different sessions and locations at the conference.

Positive

• Pipeline advancement with three distinct therapeutic candidates in development
• ELVN-002 shows potential for enhanced combination therapy in HER2 treatment
• ELV-3111 demonstrates ability to address BRAF inhibitor resistance

Negative

• None.

News Market Reaction

+0.86%

1 alert

+0.86% News Effect

On the day this news was published, ELVN gained 0.86%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.

Poster Presentation Details 

Abstract 4712 – ELVN-002, a potent, selective HER2 inhibitor with a differentiated binding mode conferring the potential for enhanced efficacy in combination with HER2-targeting antibody-drug conjugates
Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDT
Session: Targeted Therapies and Combinations 2
Location: Poster Section 34

Abstract 4361 – Development and application of a mechanistic pharmacokinetic pharmacodynamic (PKPD) model to predict anti-chronic myeloid leukemia (CML) effects of tyrosine kinase inhibitors
Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDT
Session: Pharmacokinetics and Pharmacodynamics of Cancer Therapeutics
Location: Poster Section 20

Abstract LB295 – ELV-3111, a type 1 pan-RAF inhibitor, that safely combines with MEK inhibitors for enhanced anti-tumor activity in NRAS and BRAF mutant cancers including the most common mechanisms of BRAF inhibitor clinical resistance
Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDT
Session: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Location: Poster Section 52

Abstract LB294 – Mechanism of tumor-selective inhibition of dimeric RAF by a Type 1 RAF inhibitor
Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDT
Session: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Location: Poster Section 52

Abstract 5515 – ELVN-001, a highly selective ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia alone or in combination with asciminib
Date/Time: Tuesday, April 29, 2025, 2:00 p.m. – 5:00 p.m. CDT
Session: Drug Resistance in Molecular Targeted Therapies 3
Location: Poster Section 17

Abstracts are currently available on the AACR website. Following the presentations, copies will be available on the "Program Presentations & Publications" section of the Company's website at www.enliventherapeutics.com.

About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.

View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting-302419011.html

SOURCE Enliven Therapeutics, Inc.

FAQ

What therapeutic candidates will Enliven (ELVN) present at AACR 2025?

Enliven will present data on ELVN-002 (HER2 inhibitor), ELVN-001 (ABL1 inhibitor), and ELV-3111 (pan-RAF inhibitor), along with two mechanistic studies.

When and where will Enliven Therapeutics (ELVN) present at AACR 2025?

Enliven will present five posters on April 29, 2025, at the AACR Annual Meeting in Chicago, Illinois.

What is the potential advantage of ELVN-002 in HER2 treatment?

ELVN-002 shows potential for enhanced efficacy when combined with HER2-targeting antibody-drug conjugates due to its differentiated binding mode.

How does Enliven's ELV-3111 address BRAF inhibitor resistance?

ELV-3111, a type 1 pan-RAF inhibitor, can safely combine with MEK inhibitors to combat common mechanisms of BRAF inhibitor clinical resistance.